Affymax Jumps Most in 16 Months on FDA Anemia-Drug Review

Affymax surged the most in the 16 months after U.S. regulators said the company’s experimental anemia medicine works as well as drugs sold by Amgen and Johnson & Johnson for chronic kidney disease.
Bloomberg